Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Vietnam Investment Review on MSN20h
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaLion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...
Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback